Epsilon M&A Deal Report - CRO services division of Galapagos NV (Argenta and BioFocus)
Transaction Multiples for the Valuation of Private Companies
Charles River Laboratories International / CRO services division of Galapagos NV (Argenta and BioFocus)
No EMAT :
63103
Announced Date :
13/03/2014
Type :
Acquisition of Majority Stake
Deal Value :
Yes
Acquirer :
Charles River Laboratories International
Target :
CRO services division of Galapagos NV (Argenta and BioFocus)
Country :
Netherlands
Sector of activity :
- Laboratories > Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Biomedical Research Laboratory
Business Description :
CRO services division of Galapagos NV includes both Argenta and BioFocus . > Argenta and BioFocus provide a full suite of drug discovery services from target discovery through the delivery of...
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | 
|
|
||||||
| Current |
|
Rating :
**
|
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Biomedical Research Laboratory » = 34
| Date | Acquirer | Target | Country | Multiples | See details |
| 06/01/2014 | Henry Schein | Five Arseus companies in Belgium, France and the Netherlands | Belgium | * | 63097 |
| 21/05/2013 | Private Group led by Novo A/S | Xellia Group (Xellia Pharmaceuticals) | Norway | ** | 62943 |
Source: Epsilon Research / EMAT
